指南与共识糖尿病

HbA1c用于糖尿病前期和糖尿病筛查后的实践变化

Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c Testing.
指南 / 共识 · Diabetes Care · 2019-02-06

该研究分析了2010年HbA1c被推荐用于筛查和诊断后,某大型学术医疗系统内≥45岁无糖尿病会员的筛查实践。共12,772名合格患者中78%至少筛查一次,HbA1c作为初始筛查仅占14%,葡萄糖占86%。HbA1c筛查异常者后续被诊断糖尿病前期或糖尿病的比例高于葡萄糖筛查异常者。

要点

  • HbA1c作为初始筛查的比例仍低于血糖检测
  • HbA1c异常者后续临床诊断率高于血糖异常者
  • 需更多证据明确随机血糖筛查的角色与切点

核心结论

  • 自2010年HbA1c被推荐用于筛查后,筛查率仍高,但HbA1c用于筛查的频率低于葡萄糖,且更可能导致临床诊断。

研究设计与样本

  • 回顾性队列研究,纳入某健康维护组织≥45岁、连续入组≥3年且由大型学术健康系统初级保健医生管理的无糖尿病患者。
  • 筛查定义为2010年至2014年间首次进行的口服葡萄糖耐量试验、HbA1c或血糖检测。

主要发现

  • 12,772名合格患者中,9,941名(78%)在3年内至少筛查一次。
  • HbA1c作为初始筛查占14%,葡萄糖占86%。
  • HbA1c筛查者中63%结果异常(HbA1c≥5.7%或≥39 mmol/mol)。
  • 葡萄糖检测者中30%结果异常(血糖≥100 mg/dL),5%血糖≥126 mg/dL。
  • HbA1c异常者与血糖≥126 mg/dL者预约随访比例相似(41% vs. 39%),但HbA1c异常者被诊断糖尿病前期或糖尿病的比例更高(36% vs. 26%)。

临床怎么用

  • 临床筛查中HbA1c使用率低于血糖检测,但HbA1c异常者更易获得糖尿病前期或糖尿病诊断。
  • 对于HbA1c异常者应重视随访和诊断评估。

局限性

  • 研究基于单一健康维护组织会员,结果外推需谨慎。
  • 筛查定义仅基于首次检测,未考虑后续重复检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Screening involves the presumptive identification of asymptomatic individuals at increased risk for unrecognized disease. We examined changes in screening practices for prediabetes and diabetes since January 2010, when HbA1c was first recommended as an option for screening and diagnosis. RESEARCH DESIGN AND METHODS: We studied members without diabetes of an HMO ≥45 years of age continuously enrolled for ≥3 years and assigned to primary care clinicians affiliated with a large academic health system. We defined screening as the first oral glucose tolerance test, HbA1c, or glucose test performed between 2010 and 2014. RESULTS: Of 12,772 eligible patients, 9,941 (78%) were screened at least once over 3 years. HbA1c was the initial screening test 14% of the time and glucose 86% of the time. Of those screened with HbA1c, 63% had abnormal results defined as HbA1c ≥5.7% (≥39 mmol/mol). Of those tested with glucose, 30% had abnormal results defined as glucose ≥100 mg/dL, and 5% had abnormal results defined as glucose ≥126 mg/dL. Patients with abnormal HbA1c levels and those with glucose levels ≥126 mg/dL were equally likely to be scheduled for follow-up appointments (41% vs. 39%), but those with abnormal HbA1c levels were more likely to be diagnosed with prediabetes or diabetes (36% vs. 26%). CONCLUSIONS: As we observed in 2004, rates of screening are high. HbA1c is still used less frequently than glucose for screening but is more likely to result in a clinical diagnosis. Evidence to support guidelines to define the role of random glucose screening, including definition of appropriate cut points and follow-up, is needed.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Evron JM, Herman WH, McEwen LN, et al. Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c Testing. Diabetes Care. 2019. PMID: 30728220. doi:10.2337/dc17-1726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。